Advertisement

Topics

ImmunoGen Company Profile

16:43 EST 18th November 2017 | BioPortfolio

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.

Location

128 Sidney Street
Cambridge
MA
02139
United States of America

Contact

Phone: (617) 995-2500
Fax: 617-995-2510


News Articles [62 Associated News Articles listed on BioPortfolio]

Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

http://dailystocktracker.com/register/ ImmunoGen On Wednesday, shares in Waltham, Massachusettsheadquartered ImmunoGen Inc. climbed 0.90%, ending the day at $5.59. The stock recorded a trading vol...

Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More

ImmunoGen has yet to bring one of its own antibody cancer drugs to market, but the Waltham, MA, company has had some success with its pharma partners. On Tuesday it added Jazz Pharmaceuticals to the m...

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

But it's been a really great year for Immunogen The past is the past, though. Which of these cancer-focused biotech stocks is the better choice for investors now? Here's how Exelixis and Immun...

ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4. ...

For InvestorsImmunoGen, Inc.Sarah Kiely, 781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen, Inc.Courtney O’Konek, 781-895-0158courtney.okonek@immunogen.comorFTI Consulting, Inc...

In The Spotlight: ImmunoGen

Shares of ImmunoGen Inc. (IMGN) are up an impressive 160% year-to-date compared to a gain of just 17.5% by the iShares NASDAQ Biotechnology Index (IBB) during the same period.

ADC update: Jazz teams with ImmunoGen, Genmab inks pact with SeaGen

Jazz Pharmaceuticals has become the latest firm to team with ImmunoGen in an antibody-drug conjugate (ADC) collaboration.

ImmunoGen grants Jazz rights to antibody-drug conjugate programs

Jazz Pharmaceuticals was granted an exclusive option to develop and commercialize ImmunoGen's IMGN779, IMGN632 and a third un -More- 

ImmunoGen and Jazz enter ADC option agreement

ImmunoGen Inc. granted Jazz Pharmaceuticals PLC options to license exclusive global rights to up to three antibody-drug conjugates in development for blood cancers.

Drugs and Medications [0 Results]

None

PubMed Articles [25 Associated PubMed Articles listed on BioPortfolio]

Doses of Immunogen Contribute to Specificity Spectrums of Antibodies against Aflatoxin.

Research about antibody specificity spectra was conducted to develop single-specific antibodies or broad-specific antibodies. Aflatoxins, as one class of high-toxicity mycotoxins, were selected as the...

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.

Durability of vaccine-elicited immune responses is one of the key determinants for vaccine success. Our aim is to develop a vaccination strategy against the human immunodeficiency virus type 1 (HIV-1)...

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and e...

Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

Eliciting broadly neutralizing antibody (bNAb) responses against HIV-1 is a major goal for a prophylactic HIV-1 vaccine. One approach is to design immunogens based on known broadly neutralizing epitop...

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Antigenic drift and shift of influenza strains underscore the need for broadly protective influenza vaccines. One strategy is to design immunogens that elicit B cell responses against conserved epitop...

Clinical Trials [26 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Safety and Efficacy of G17DT Immunogen in the Treatment of Advanced Pancreatic Carcinoma

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymp

To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched pept...

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine

The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are s...

Companies [7 Associated Companies listed on BioPortfolio]

ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agent...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunocon...

Industrial Research Limited - UK

IRL Biopharm is a highly skilled contract manufacturing business focused on developing and manufacturing novel secondary metabolites for our growing number of biotech and pharma clients around the glo...

Immunitor Corporation Co., Ltd

Immunitor Corporation Co., Ltd., is the first private biotech company formed in Thailand Technology developed by Immunitor allows to formulate any desired immunogen or antigen as an or...

Vical Incorporated

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applica...

More Information about "ImmunoGen" on BioPortfolio

We have published hundreds of ImmunoGen news stories on BioPortfolio along with dozens of ImmunoGen Clinical Trials and PubMed Articles about ImmunoGen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoGen Companies in our database. You can also find out about relevant ImmunoGen Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record